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Discovery of Radioiodinated 
Monomeric Anthraquinones as a 
Novel Class of Necrosis Avid Agents 
for Early Imaging of Necrotic 
Myocardium
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Assessment of myocardial viability is deemed necessary to aid in clinical decision making whether to 
recommend revascularization therapy for patients with myocardial infarction (MI). Dianthraquinones 
such as hypericin (Hyp) selectively accumulate in necrotic myocardium, but were unsuitable for early 
imaging after administration to assess myocardial viability. Since dianthraquinones can be composed 
by coupling two molecules of monomeric anthraquinone and the active center can be found by splitting 
chemical structure, we propose that monomeric anthraquinones may be effective functional groups for 
necrosis targetability. In this study, eight radioiodinated monomeric anthraquinones were evaluated as 
novel necrosis avid agents (NAAs) for imaging of necrotic myocardium. All 131I-anthraquinones showed 
high affinity to necrotic tissues and 131I-rhein emerged as the most promising compound. Infarcts were 
visualized on SPECT/CT images at 6 h after injection of 131I-rhein, which was earlier than that with 131I-
Hyp. Moreover, 131I-rhein showed satisfactory heart-to-blood, heart-to-liver and heart-to-lung ratios for 
obtaining images of good diagnostic quality. 131I-rhein was a more promising “hot spot imaging” tracer 
for earlier visualization of necrotic myocardium than 131I-Hyp, which supported further development 
of radiopharmaceuticals based on rhein for SPECT/CT (123I and 99mTc) or PET/CT imaging (18F and 124I) of 
myocardial necrosis.
Coronary artery disease (CAD) is a major cause of mortality worldwide, resulting in 8.14 million deaths (16.8%) 
in 20131. CAD occurs when the arteries that supply blood to myocardium become hardened and narrowed. 
Timely revascularization as the most effective therapy for patients may restore adequate blood flow, improve 
cardiac function, prevent further deterioration in left ventricular function and reduce the risk of sudden death2,3. 
Although revascularization has served to reduce the overall mortality from CAD, it is not always appropriate for 
all patients. The Occluded Artery Trial (OAT) is a multicenter, international and randomized study that designed 
to test routine coronary intervention after myocardial infarction (MI). The results of OAT show that revascu-
larization has no curative benefit for some patients with little reversibly viable myocardium in infarcted areas. 
Re-infarctions (approximately 10% of re-infarctions being rapidly fatal) and serious reperfusion injury tend to 
happen at a higher rate in those patients randomized to myocardial revascularization4–7. Therefore, the assess-
ment of myocardial viability is deemed necessary to aid in revascularization therapy and to improve the outcome 
of patients with CAD.
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Non-invasive cardiac imaging plays an important role in anatomical and functional evaluations of MI. In 
clinical practice, most tracers used for the assessment of myocardial viability are usually through two main physi-
ologic mechanisms: myocardial perfusion and cellular metabolism in viable areas8. 18F-FDG is a gold standard for 
the evaluation of viability, which is based on segmental differences in perfusion and metabolism to differentiate 
normal, dysfunctional but viable and necrotic myocardium. However, the results are likely to be false negatives 
and positives due to the uptake of 18F-FDG are easily influenced by the glucose concentration, insulin level and 
metabolism of individuals9.
The imaging of necrotic myocardium may enable the evaluation of MI by assuring the proportions of irrevers-
ibly infarcted versus jeopardized but still viable viability myocardium10,11. Relative to programmed cell death or 
apoptosis which is detectable with annexin V tracers but less relevant to acute MI12, necrosis is a common type of 
cell death and is characterized by irreversible loss of plasma membrane integrity with cells welling and rupture, 
leading to release of intracellular contents13. Some components such as exposed DNA, histones, phosphatidyl-
serine, etc. released from necrotic tissues are potential targets for the identification of necrotic myocardium to 
assess myocardial viability13,14. Necrosis avid agents (NAAs) selectively accumulate in necrotic tissues, which 
could be exploited for “hot spot imaging” of necrotic myocardium to measure non-viable infarcted areas15 and to 
estimate prognosis16. Moreover, radioscintigraphic NAAs in trace amount may prevent dysfunctional but viable 
myocardium from the further damage caused by excessive uptake of contrast agents for other less sensitive imag-
ing modalities8. 99mTc-pyrophosphate17, 111In-antimyosin Fab antibody18 and 99mTc-glucarate19 have been used to 
localize and quantify myocardial necrosis in patients. But they have not been widely accepted in the clinic because 
they cannot fulfill these requirements: high avidity and specificity, rapid localization at the infarct and reasonable 
duration of scan positivity.
Recently, hypericin (Hyp)10, protohypericin20 and Sennidin A21, which are polyphenolic polycyclic dianthrone 
compounds (Fig. 1), have been recognized as prominent NAAs. As candidate positive tracers for imaging of 
necrotic myocardium, they showed high affinity for necrotic tissues after being labeled with radionuclides10,15,20–24. 
However, the long plasma half-life time of radio-labelled Hyp with high blood pool activity in vivo would make 
it unsuitable for early imaging of necrotic myocardium after administration. Although high imaging contrast 
between infarcted and viable myocardium reached at 9 h after injection15, clear visualization of necrotic myocar-
dium was not possible within the clinically relevant time window for thrombolytic therapy (usually within 6 h of 
the acute event), which is the problem that need to be solved in clinical practice.
In this context, there is a pressing need for finding novel NAAs with the potential for early imaging of necrotic 
myocardium. Hyp, protohypericin and Sennidin A, all showing specific necrosis affinity, are composed by cou-
pling two molecules of monomeric anthraquinone in different ways25,26. Based on the evidence that the active 
center can be found by splitting chemical structure27, monomeric anthraquinones may be effective functional 
groups for necrosis targetability, which share simplified structures and shorter plasma half-life times28–30. Hence, 
we speculated that monomeric anthraquinones may also feature necrosis targetability and could be used for imag-
ing of necrotic myocardium earlier than Hyp.
To validate this hypothesis, we selected eight monomeric anthraquinones (Fig. 2) and labelled them with 
iodine-131, evaluated the necrosis targetability. We further validated the potential of a lead compound for assess-
ment of myocardial necrosis by SPECT/CT imaging and enzymatic histochemical staining with triphenyltetra-
zolium chloride (TTC).
Figure 1. Chemical structures of reference compounds. 
Figure 2. Chemical structures of eight monomeric anthraquinones. 
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Results
Chemistry of mono-iodorhein. The structural elucidation of mono-iodorhein was determined by 1H, 13C 
NMR and HR-ESI-MS experiments (Supplementary Fig. S1–3), indicating that H-7 on the aromatic ring has been 
replaced by the iodine atom. 1H NMR (300 MHz, DMSO-d6) δ (ppm): 8.36 (d, J = 7.5 Hz, 1H, H-6), 8.14 (s, 1H, 
H-4), 7.79 (s, 1H, H-2), 7.48 (d, J = 7.8 Hz, 1H, H-5); 13C NMR (300 MHz, DMSO-d6) δ (ppm): 191.2 (C-9), 181.0 
(C-10), 165.5 (-COOH), 161.3 (C-8), 160.4 (C-1), 146.8 (C-6), 138.5 (C-3); 134.1 (C-4a), 133.3 (C-10a), 124.6 
(C-2), 120.6 (C-5), 119.0 (C-4), 118.7 (C-8a), 115.9 (C-9a), 96.3 (C-7). HR-ESI-MS: calculated for [C15H7O6I]: 
408.9209 [M− H]−; found 408.9215 [M− H]−.
Radiochemistry and in vitro stability. The Iodogen coating method was conducted successfully 
in this study. Radiochemical yields of 131I-1-hydroxyanthraquinone, 131I-alizarin, 131I-danthron, 131I-rhein, 
131I-aloe-emodin, 131I-chrysophanol, 131I-emodin and 131I-physcion were 92.13% ± 0.53%, 97.49% ± 0.47%, 
93.93% ± 0.59%, 96.71% ± 0.43%, 96.15% ± 0.46%, 95.01% ± 0.51%, 99.32% ± 0.59% and 94.27% ± 0.42% (with-
out purification) respectively as determined by TLC shown in Supplementary Fig. S4. All 131I-anthraquinones 
turned out to be stable after incubation in rat plasma at 37 °C for 24 h with the data of 87.93% ± 0.45%, 
93.17% ± 0.49%, 90.14% ± 0.48%, 93.17% ± 0.38%, 91.90% ± 0.43%, 90.04% ± 0.49%, 98.72% ± 0.46% and 
91.06% ± 0.38%, respectively.
Chemical purity and in vitro stability by HPLC. HPLC analysis showed the retention time of 
mono-iodorhein was 9.08 min (Fig. 3a), which was consistent with that of 131I-rhein as 9.14 min (Fig. 3b). 
Radiochemical purity of 131I-rhein was 95.27% ± 0.53% as detected with HPLC by quantifying peaks correspond-
ing to the free 131I and 131I-rhein. The in vitro stability data showed 91.75% ± 0.47% of the intact parent tracer 
after 24 h incubation in rat serum (Fig. 3c), indicating that 131I-rhein was stable in rat plasma till the detection 
endpoint. The results of radiochemical purity and in vitro stability of 131I-rhein determined by radio-HPLC were 
consistent with that by TLC.
Biodistribution studies of mice. The biodistribution results of all 131I-anthraquinones were shown in 
Supplementary Table S1–2. These tracers showed different necrosis targetability in vivo and the uptakes of all 
Figure 3. HPLC chromatograms of mono-iodorhein or 131I-rhein. (a) ultraviolet-chromatogram of mono-
iodorhein; (b) radiochemical purity of 131I-rhein in injection preparation; (c) in vitro stability of 131I-rhein after 
24 h incubation in rat serum at 37 °C.
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131I-anthraquinones by necrotic muscle were significantly higher than that by viable muscle at three time points 
(P < 0.01). The radioactivity ratio of necrotic to viable muscle for each tracer at 24 h post-injection (p.i.) was 
higher than that at 2 h or 12 h p.i. (P < 0.05). Relatively high uptakes of eight 131I-anthraquinones were detected 
in organs/tissues such as necrotic muscle, blood, liver, kidney and stomach while viable muscle and heart showed 
the lowest uptake at 2 h p.i. These data displayed an obvious clearance of radioactivity from all normal organs 
within 24 h except for the kidney and liver, indicating that these tracers were mainly metabolized and/or excreted 
by such dual pathways.
The concentrations of 131I-rhein in necrotic vs viable muscle were 4.61 ± 0.39%ID/g vs 0.79 ± 0.08%ID/g, 
4.06 ± 0.16%ID/g vs 0.56 ± 0.04%ID/g and 0.74 ± 0.04%ID/g vs 0.06 ± 0.00%ID/g at 2 h, 12 h and 24 h after 
administration with the corresponding radioactivity ratios from necrotic to viable muscle were 5.84 ± 0.10, 
7.26 ± 0.23 and 12.33 ± 0.67, respectively. The necrotic uptake and radioactivity ratio of 131I-rhein were the high-
est than that of other seven tracers at three time points (P < 0.01). The clearance of 131I-rhein from normal organs 
was also favorable for imaging purpose.
Outcomes of TTC staining and autoradiograhy. Figure 4 displays close matches between TTC stained 
slices and corresponding autoradiograms from model mice sacrificed at 24 h after administrations of all eight 
tracers. On the TTC-stained specimens, the necrotic muscles remained pale whereas normal muscles were 
stained brick red. The high radioactivity uptakes (in red) primarily appeared in necrotic regions on autoradi-
ographs, which were in accordance with pale areas on TTC-staining images. By quantitative autoradiography 
analyses, the necrotic/viable muscle ratios of 131I-1-hydroxyanthraquinone, 131I-alizarin, 131I-danthron, 131I-rhein, 
131I-aloe-emodin, 131I-chrysophanol, 131I-emodin and 131I-physcion were 9.16 ± 0.78, 9.84 ± 0.89, 9.93 ± 0.83, 
17.64 ± 1.28, 11.08 ± 0.91, 10.34 ± 0.86, 9.61 ± 0.72 and 8.14 ± 0.79, respectively. These data were consistent with 
the results of biodistribution studies. Among these tracers, 131I-rhein showed the highest necrotic/viable muscle 
ratio at 24 h after administration (P < 0.05).
The results obtained from biodistribution, TTC staining and autoradiography indicated that all eight 
131I-anthraquinones selectively accumulated in necrotic muscles and 131I-rhein appeared to be the best radiop-
harmaceutical NAA, which encouraged us to further evaluate it by in vivo SPECT/CT imaging in rats with MI.
Pharmacokinetics study in normal rats. The elimination half-life (t1/2z) of 131I-rhein was 8.20 ± 0.49 h, 
which presents a relatively fast clearance from blood circulation. The radioactivity concentration of 131I-rhein 
in blood at 6 h decreased to 23.47% ± 1.91% of peak radioactivity concentration. The major pharmacokinetic 
parameters are given in Table 1.
SPECT/CT imaging of rats. The in vivo SPECT/CT images of rats with reperfused MI or sham operation 
at 6 h after administration of 131I-rhein or 131I-Hyp are exemplified in Fig. 5. Relatively high uptake as a hot spot 
showed up in the heart of the model rat, while no obvious uptake was observed in the heart of the control rat, 
Figure 4. TTC staining images and autoradiographs of eight tracers from mice sacrificed 24 h after 
administration. On the TTC-stained images, the necrotic muscles remained pale whereas normal muscles 
were stained brick red. The high radioactivity uptakes (in red) primarily appeared in necrotic regions on 
autoradiograms, which were in accordance with pale areas on TTC staining images. (a–h) were represented 
131I-1-hydroxyanthraquinone, 131I-alizarin, 131I-danthron, 131I-rhein, 131I-aloe-emodin, 131I-chrysophanol, 
131I-emodin and 131I-physcion, respectively.
Parameter Unit Value for normal rats
AUC(0 –t) MBq/L*h 187.46 ± 28.26
AUC(0 –∞) MBq/L*h 211.76 ± 31.18
t1/2z h 8.20 ± 0.49
Tmax h 0.08 ± 0
CLZ L/h/kg 0.04 ± 0.01
Cmax MBq/L 42.40 ± 5.41
VZ L/kg 0.42 ± 0.06
Table 1.  Blood clearance of 131I-rhein. Major pharmacokinetics parameters of 131I-rhein derived by the 
statistical moment method of the non-compartment model in normal rats within 24 h after intravenous 
injection at a dose of 3.7 MBq each rat (n = 6). AUC(0–t) and AUC(0–∞): area under the curve; t1/2z: elimination 
half-life; Tmax: peak time; CLZ: clearance; Cmax: peak concentration. The values are expressed as mean ± SD.
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indicating a selective accumulation of 131I-rhein in necrotic myocardium. Prominent activity was seen in stomach 
likely due to the gastric excretion of the free iodide (131I). With 131I-Hyp, due to the high blood pool activity at 
6 h p.i., relatively high radioactivity was observed in the heart of the model rat and the sham operation rat, which 
could not distinguish between viable and necrotic myocardium. Moreover, the high activity of 131I-Hyp in the 
liver may compromise the imaging accuracy of necrotic myocardium.
Biodistribution of 131I-rhein and 131I-Hyp in model rats. Figure 6a reveals a high and specific radi-
oactivity uptake of 131I-rhein in necrotic myocardium at 6 h p.i. The radioactivity concentration of 131I-rhein 
in infarcted myocardium was 1.18 ± 0.03%ID/g, which was about 9.81 ± 0.61 times higher than that in viable 
myocardium (0.12 ± 0.01%ID/g). Prominent activity was detected in the kidney (0.68 ± 0.04%ID/g), indicating 
a major renal pathway for this tracer. The radioactivity concentration of 131I-rhein in blood, lung and liver were 
0.36 ± 0.03%ID/g, 0.24 ± 0.02%ID/g and 0.14 ± 0.01%ID/g, respectively, all were lower than the radioactivity 
in necrotic myocardium (P < 0.01), suggesting 131I-rhein as a promising imaging tracer of MI with satisfactory 
heart-to-blood, heart-to-liver, and heart-to-lung ratios.
When compared with 131I-rhein, 131I-Hyp had higher viable myocardium uptake (0.37 ± 0.03%ID/g) and the 
lower necrotic/viable myocardium ratio of 4.03 ± 0.03 at 6 h p.i. (P < 0.01). Higher radioactivity concentrations of 
131I-Hyp were detected in blood (0.85 ± 0.08%ID/g), lung (2.02 ± 0.14%ID/g) and liver (0.83 ± 0.09%ID/g) than 
that of 131I-rhein (P < 0.01), which would compromise the imaging of MI at 6 h p.i. These data were consistent 
with the results of SPECT/CT images.
Histopathological staining and autoradiography of MI. The histopathological results of 131I-rhein 
from model rats were shown in Fig. 6b–e. On the TTC-stained slice (Fig. 6b), the infarcted myocardium remained 
pale whereas viable myocardium was stained brick red. The infarcted areas involve the lateral wall of the left ven-
tricle (TTC negative). A homogenous high radioactivity uptake (in red) only occurred in the infarcted areas on 
Figure 5. SPECT/CT imaging of 131I-rhein or 131I-Hyp (as a positive control agent) in rats with reperfused 
MI or sham operation. SPECT/CT-fused images showed high uptake of 131I-rhein in the MI and no obviously 
high radioactivity in viable myocardium, relatively high radioactivity of 131I-Hyp was observed in heart and liver 
of model rat or sham operation rat. Red arrows indicate the heart.
Figure 6. Biodistribution and postmortem analyze of MI in rats. (a) Biodistribution of 131I-rhein or 131I-Hyp 
at 6 h after administration (n = 5 per tracer). Data are expressed as average percentage of injected dose per gram 
(%ID/g) ± SD: Viable.m = viable myocardium, Necrotic.m = necrotic myocardium; (b–e) Postmortem analyze 
of necrotic and viable myocardium from model rats of 131I-rhein: (b) TTC staining image of 2 mm thick slice;  
(c) autoradiogram from 50 μ m frozen section; (d) H&E staining image of 10 μ m frozen section; (e) H&E-
stained microphotograph proved the presence of necrosis: N = necrotic area, V = viable area.
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autoradiograph (Fig. 6c), which corresponded well to the pale region on TTC stained specimen. Quantitatively, 
14-fold higher activity was found in infarcted myocardium than that in viable myocardium. The H&E staining 
(Fig. 6d) and photomicrograph (Fig. 6e) confirmed the presence of necrosis.
Discussion
In this study, we identified monomeric anthraquinones as a new class of NAAs, which have simpler structures 
compared to other recently reported tracers31. These novel agents showed prominent targetability to necrotic 
tissues in animal models. Among these NAAs, 131I-rhein emerged as the most promising compound to be an 
excellent “hot spot imaging” tracer potentially for imaging of necrotic myocardium to deduce myocardial viabil-
ity. Moreover, the timing for visualizing necrotic myocardium with 131I-rhein was earlier than that with 131I-Hyp.
We selected mice model of muscular necrosis to screen the necrosis affinity among eight monomeric anth-
raquinones with radioiodination. All data indicated prominent targetability of eight 131I-anthraquinones to 
necrotic tissues, with highly sustaining necrotic to viable tissues radioactivity ratios and efficient clearance of 
radioactivity from non-target organs. Furthermore, the substituents in their aromatic ring appear to have impact 
on their necrosis targetability. The necrotic/normal radioactivity ratios and the necrotic uptake with 131I-rhein 
were the highest than that with other seven tracers, indicating that the carboxyl group at the 3-position might 
favor the necrosis targetability.
Based on the results above, we selected 131I-rhein as a candidate lead compound to explore its imaging poten-
tials in rat model of MI. 131I-rhein (t1/2z = 8.20 h) showed a relatively faster clearance from blood circulation than 
131I-Hyp (t1/2z = 30.48 h)22, which facilitated the early visualization of infarcts. In the previous study, images of 
high contrast between infarcted and viable myocardium were obtained at 9 h after injection of radio-labelled Hyp 
and visualization of necrotic myocardium was not possible at earlier stage due to high blood pool activity15. These 
results are consistent with this study that 131I-Hyp could not cause hot spot imaging of necrotic myocardium at 
6 h after administration. By contrast, we obtained good quality images that visualized necrotic myocardium at 6 h 
after 131I-rhein administration. According to the biodistribution data, the radioactive uptakes in blood, liver and 
lung were much lower than that in infarcted myocardium, suggesting satisfactory heart-to-blood, heart-to-liver 
and heart-to-lung ratios with 131I-rhein in model rats and this may be the major reason for obtaining images of 
good quality. However, images of 131I-Hyp looked poor due to the high uptakes in blood, liver and lung that are 
near the heart, which may compromise the diagnostic capacity.
If 131I-rhein can be used for imaging of necrotic myocardium in patients at 6 h after administration, the 6 h 
time window presented in this study deems clinically relevant as thrombolytic therapy is routinely performed 
prior to visualization and sizing of infarcted areas after the patients are admitted to the emergency unit. Rapid 
time to thrombolysis treatment within 6 h after MI could be an important determinant for the patient survival 
with reduced mortality and disability32,33. Clear demarcation of irreversibly infarcted and the ischemic but still 
viable myocardium (salvageable tissue at risk of infarction) should be obtained before thrombolysis is initiated 
within 6 h. Therefore, the performance that 131I-rhein has demonstrated in this study could allow the rapidly use 
of interventions for myocardial salvage through imaging of necrotic myocardium to assess myocardial viability, 
thereby improving the clinical outcomes of treatment.
Some tracers have been used for imaging of myocardial necrosis in patients34. Like 131I-rhein, most tracers 
made full use of membrane disruption, the hallmark of necrosis as a target. 99mTc-pyrophosphate was feasible 
for necrosis imaging at 3 h p.i., but the maximal uptake in the necrotic myocardium occurs at 24–72 hours after 
infarction35. This tracer also required residual blood flow, which prevented uptake in the infarct center for a full 
picture of necrosis36. 99mTc-glucarate has good imaging characteristics of necrotic myocardium, but its use is 
limited to 9 hours after onset, because the target of this tracer is histone that is quickly washed out from necrotic 
tissues19. In this regard, 131I-rhein seems a potential NAA for imaging of necrotic myocardium and needs to be 
further evaluated in follow-up studies.
Further studies are necessary to determine the earliest time point after radiolabeled rhein administration, at 
which diagnostically useful images can be obtained. Although iodine-131 emits both β -particles and γ -rays that 
can be used for diagnosis and therapy of cancer and hyperthyroidism, the beta emission may cause damage to 
adjacent normal myocardium hence enlarge the infarcted areas. In the present study, we have demonstrated that 
all 131I-anthraquinones showed necrosis targetability at 2 h p.i., so we intend to label rhein with these radionu-
clides (18F, 99mTc, 123I) that share shorter half-life times for early imaging of necrotic myocardium in the future. We 
will use 18F-FDG-PET/CT (a viability tracer) to compare with 131I-rhein-SPECT/CT (a necrosis avid tracer) to 
further confirm the potential of 131I-rhein for the assessment of myocardial viability in the next study.
These new radioiodinated monomeric anthraquinone tracers showed peculiar affinity to necrotic tissues in 
animal models. We have successfully validated that 131I-rhein possessed the diagnostic potential for earlier assess-
ment of myocardial viability through “hot spot imaging” of infarcted myocardium in model rats than 131I-Hyp. 
We consider that radiolabeled rhein represents a new lead compound, worthy of further research toward the ulti-
mate aim of identifying a clinical candidate suitable for SPECT/CT or PET/CT imaging of necrotic myocardium 
to assess myocardial viability.
Methods
Materials and reagents. Kunming mice (male, 22–26 g) and Sprague-Dawley rats (male, 260–280 g) were 
provided by the Experimental Animal Center of Academy of Military Medical Sciences. The Institutional Animal 
Care and Use Committee approved the project. The care and treatment of all animals were maintained in accord-
ance with NIH publication No.85–23 (revised in 1996) on “Principles of laboratory animal care”. Eight anthraqui-
nones were commercially available from Chendu SinoStandards Biological Technology Co., Ltd. (Chendu, China) 
with purity greater than 97%. Sodium iodide’s (Na131I) radionuclidic purity was > 99% and specific activity was 
370 MBq/mL, which was supplied by HTA Co., Ltd. (Beijing, China).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:21341 | DOI: 10.1038/srep21341
Reversed-phase high performance liquid chromatography (RP-HPLC) was equipped with Waters 2998 PDA 
detector, HERM LB500 radiometric detector (Berthold Technologies, Germany), a pump (Waters 2695) and a 
Alltima C18 column (250 × 4.6 mm, 5 μ m, GRACE). The mobile phase was methanol/0.1% phosphoric acid in 
water (80:20, v/v), the flow rate was 1.0 mL/min and the temperature of column was 30 °C. All solvents used for 
HPLC analysis were HPLC grade.
Synthesis of mono-iodorhein. I2 (317 mg, 1.25 mmol) and HIO3 (220 mg, 1.25 mmol) were added to the 
mixture of rhein (284 mg, 1 mmol) in 1,4-dioxane (40 mL) and water (8 mL) (Fig. 7). The reaction mixture was 
heated to reflux for 24 h before cooling to room temperature and pouring into water (500 mL). The precipitate was 
collected by vacuum filtration and purified by semipreparative RP-HPLC (methanol: 0.5% three fluorine acetic 
acid in water = 75:25) to give mono-iodorhein (110 mg, 0.27 mmol, 26.85%) as an orange red solid. Its structural 
elucidation was determined by 1H, 13C NMR and HR-ESI-MS experiments.
Radiochemistry and in vitro stability. Iodogen (1, 2, 4, 6-tetrachloro-3a, 6a-diphenylglycouracil; Sigma, 
St. Louis, MO) was dissolved in dichloromethane and deposited on the wall of tubes as a thin film. Radioiodination 
was initiated by adding dimethylsulfoxide (DMSO) solutions of each anthraquinone (1.25 mg/mL) 
and Na131I solutions (4:1, v/v) into Iodogen-coated tube, adjusting pH with phosphate buffered saline (PBS, pH 
7.4). Then these mixtures were shaken and incubated at 45 °C for 2–4 h, and radiochemical purity was determined 
by thin-layer chromatography (TLC) using Whatman No.1 filter paper and 0.1 M hydrochloric acid as the devel-
oping solvent. Then the solvent was evaporated, the paper was cut in half and measured the radioactivity by direct 
γ -counting (WIZARD1470; PerkinElmer, USA). For obtaining the injectants, these mixtures were diluted with 
propylene glycol and polyethylene glycol 400 (1:1, v/v), respectively.
In vitro stability of eight 131I-anthraquinones were tested in rat serum, 0.1 mL injectant was added to 0.9 mL rat 
serum (1:9, v/v) and incubated at 37 °C. Then radiolabeling stability was determined by TLC using the procedure 
described above at the time points of 0.5 h, 6 h, 12 h and 24 h, respectively.
Chemical purity and in vitro stability by HPLC. Chemical purity of mono-iodorhein or 131I-rhein. 
Chemical purity was detected by HPLC using the procedure described above. The percent of the intact 131I-rhein 
was determined by quantifying peaks corresponding to the intact and degraded products. The assay was repeated 
three times.
In vitro stability of 131I-rhein. 131I-rhein was incubated in rat serum at 37 °C for 24 h, and the mixture was mixed 
with methanol at a ratio of 2:3 and shaken. After centrifuging the mixture at 12000 rpm for 10 min, the superna-
tant was collected and passed through 0.22-μ m pore-size filters (Membrana, Wuppertal, NRW, Germany) for in 
vitro stability analysis by radio-HPLC as described above.
Animal models of necrosis. All animals were given 0.12% potassium iodide in drinking water from 3 days 
before the experiment till the end of experiment to protect the thyroid gland from taking up free 131I.
Muscular necrosis model. Each mouse was intramuscularly injected with 0.1 mL absolute alcohol in the left hind 
limb to induce muscular necrosis.
Myocardial infarction model. Sprague-Dawley rats were intraperitoneally anesthetized with 10% chloral hydrate 
(3 mL/kg of body weight), then intubated and artificially ventilated with room air using a rodent ventilator. A left 
thoracotomy was performed along the third and fourth intercostal space, followed by incision of the pericardium 
to fully expose the heart in thoracic cavity. The proximal left anterior descending coronary artery (LAD) was 
occluded by a single ligature at 1–2 mm below the junction of the pulmonary conus and the left atrial append-
age. In control rats, the suture was passed underneath the LAD without ligation. The chest wall was closed by 
suturing in layers, with the end of the suture of detachable knot externalized. Sixty minutes after LAD occlusion, 
pulling the suture end to achieve coronary reperfusion with the rat being intramuscularly injected with 80000 U 
Penicillin for preventing infection.
Tracer administration. At least 12 h after recovery from surgery, each model mouse was intravenously 
administrated with 0.37 MBq of 131I-anthraquinones and each rat was intravenously injected with 3.7 MBq of 
131I-rhein or 131I-Hyp for pharmacological evaluations. All animals were intravenously administered with 0.1 ml 
of 1% Evans blue solution for intravital staining of necrosis that helped to selectively sample bluish necrotic tis-
sues for radioactivity quantification.
Biodistribution studies in mice. One hundred and twenty model mice were randomly divided into 24 
groups for eight tracers (n = 5 per compound and per time point). Mice were sacrificed by cervical dislocation at 
Figure 7. Synthesis of mono-iodorhein. 
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2 h, 12 h and 24 h after administration. Necrotic and normal tissues of interest (blood, thyroid, lung, heart, liver, 
spleen, stomach, kidney, viable/necrotic muscle) were sampled, and wet weighed with the radioactivity meas-
ured by a γ -counter. Background radiation and physical decay were corrected during counting. The results were 
expressed as percentage of the injected dose per gram of tissue (%ID/g). Ratios of radioactivity concentrations 
between in necrotic and viable muscle were calculated.
TTC staining and autoradiograhy of normal and necrotic muscles. We further proved the presence 
of necrotic tissues with enzymatic histochemical staining using TTC on the muscles after biodistribution studies. 
The necrotic muscles were stained in 2% TTC solution at 37 °C for 15 min and digitally photographed, then cut 
into 50 μ m frozen sections with a cryotome (Shandon FSE, Thermo Fisher Scientific Co., Waltham, MA, USA) 
for autoradiography. Autoradiographs of these sections were obtained by exposure to a high-performance stor-
age phosphor screen (Cyclone; Canberra-Packard, Ontario, Canada) for 6–48 h and digitally photographed with 
Optiquant software (Pacard, Packard Meriden, CT, USA). Relative tracer concentrations in necrotic muscles were 
evaluated by regions of interest analysis and the results were compared with that from the corresponding viable 
muscles.
Pharmacokinetics study of 131I-rhein in normal rats. For the pharmacokinetic study, six healthy rats 
were intravenously injected with 131I-rhein under anesthesia. The blood samples (10 μ L) were collected by means 
of a tail incision at 5 min, 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h and 24 h after administration. The radio-
activity of blood samples was measured and the results were expressed as megabecquerel per liter (MBq/L). The 
blood pharmacokinetic parameters of the radiotracer were analyzed by using the non-compartmental analysis of 
Drug and Statistics for windows 2.0 software.
SPECT/CT imaging of rats. The SPECT/CT system (Precedence 6; Philips) consisted of a variable-angle 
dual-detector with low-energy high-resolution collimators and a multislice spiral CT component optimized for 
rapid rotation. SPECT/CT imaging was conducted at 6 h after injection of 131I-rhein or 131I-Hyp (as a positive 
control agent), MI model rats and sham operation rats were anaesthetized with intraperitoneal injection of 10% 
chloral hydrate. The SPECT acquisition (128 × 128 matrix, 30 frames) was performed using 6° angular steps in 
a 25-s time frame. For CT (120 kV, 240 mA, 0.75 s/r), 1 mm slices were obtained. After reconstruction, SPECT 
images were corrected for attenuation and scatter. Both SPECT and CT axial 1-mm slices were generated using an 
Astonish bone application package and were transferred to a picture archiving and communication systems after 
generation of DICOM files. SPECT/CT images were fused using the Syntegra software.
Biodistribution of model rats. After the scan of SPECT/CT, ten model rats (n = 5 per tracer) were imme-
diately sacrificed by overdose of anesthetic. Necrotic and normal myocardial tissues were collected, weighed and 
counted as the procedure described above.
Histopathological staining and autoradiograhy of MI. The isolated hearts from model rats having 
received 131I-rhein were imbedded in a Plexiglas heart matrix by 3% agar solution at 40 °C. A series of 2 mm sec-
tions were made in the axial plane. One half of sections were immediately stained in 2% TTC solution at 37 °C for 
15 min and digitally photographed, then were cut into 50 μ m frozen sections with a cryotome for autoradiogra-
phy as above. Slices (10 μ m) adjacent to those used for TTC staining were selected for hematoxylin-eosin (H&E) 
staining using standard techniques and digitally photographed, which were then photomicrographed under a 
bright field.
Statistical analysis. All quantitative results were expressed as mean ±  standard deviation (SD). 
Between-group or data from tissues of interest were compared by one-way analysis of variance using Student’s t 
test and P < 0.05 was considered statistically significant.
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